Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncolytics Biotech has completed patient enrollment in the dose escalation portion of its UK clinical trial to evaluate the antitumor effects of systemic administration of Reolysin in combination with docetaxel in patients with advanced cancers including bladder, prostate, lung and upper gastro-intestinal.
Subscribe to our email newsletter
The trial has two components. The first is an open-label, dose-escalating, non-randomized study of Reolysin given intravenously with docetaxel every three weeks. Standard dosages of docetaxel were delivered to patients with escalating dosages of Reolysin intravenously. The second component of the trial includes the enrollment of a further nine patients at the top dose of Reolysin in combination with a standard dosage of docetaxel.
Hardev Pandha, principal investigator, said: “We have completed the dose escalation stage of the study. Patients enrolled had previously undergone significant treatment with combination chemotherapy. The combination of Reolysin and taxotere was safe, well tolerated with no obvious toxicity related specifically to Reolysin. Efficacy of the combination was encouraging: both objective antitumor responses and disease stabilization were observed radiologically.”